Kris Jacobs Vacancies Kris Jacobs Kris Jacobs Loading jobs... Stay updated Sign up to stay updated and find out how you can get involved. Email Address Data protection consent Read, watch, share Filter by - Any -BlogEventsExplainerFact sheetFeature storyInfographicInterviewIssue briefLetterNewsletterOpinion articlePhoto storyPress releaseReportReport seriesResearch articleSpeechSpotlightStatementTechnical briefTopic overviewVideo Photograph by Yesika Ocampo Press release Press release | 29 January 2021 COVID-19 COVID-19 diagnostics: MSF welcomes more affordable rapid tests for lower- and middle-income countries 3 min 27 January 2021 Tropical & neglected diseases Overcoming Neglect Technical brief | 26 January 2021 COVID-19 United States of America Transparency Matters: Disclosing the Costs of Publicly Funded Research & Development for COVID-19 Medical Tools and Beyond Photograph by Mariana Abdalla Press release Press release | 22 January 2021 COVID-19 COVID-19 vaccines: MSF deplores just 2% of Pfizer’s 2021 & 2022 supply going to COVAX Facility 4 min Statement | 18 January 2021 Diabetes MSF Statement on EB148/6 – Non communicable diseases 2 min Statement | 18 January 2021 Tropical & neglected diseases MSF Statement on EB148/6 – Oral health and noma disease 2 min Statement | 18 January 2021 Intellectual property and trade MSF Statement on EB148/8 – Global strategy and plan of action on public health, innovation and intellectual property (GSPOA) 2 min Blog Blog | 18 January 2021 Intellectual property and trade Will history repeat itself? Load More
Photograph by Yesika Ocampo Press release Press release | 29 January 2021 COVID-19 COVID-19 diagnostics: MSF welcomes more affordable rapid tests for lower- and middle-income countries 3 min
Technical brief | 26 January 2021 COVID-19 United States of America Transparency Matters: Disclosing the Costs of Publicly Funded Research & Development for COVID-19 Medical Tools and Beyond
Photograph by Mariana Abdalla Press release Press release | 22 January 2021 COVID-19 COVID-19 vaccines: MSF deplores just 2% of Pfizer’s 2021 & 2022 supply going to COVAX Facility 4 min
Statement | 18 January 2021 Tropical & neglected diseases MSF Statement on EB148/6 – Oral health and noma disease 2 min
Statement | 18 January 2021 Intellectual property and trade MSF Statement on EB148/8 – Global strategy and plan of action on public health, innovation and intellectual property (GSPOA) 2 min
